Continuous low-dose therapy with vinblastine and VEGFR-2 antibody induces sustained tumor regression in neuroblastoma xenograft, diminishes tumor vascularity, and directs inhibition of angiogenesis [60], suggesting that metronomic therapy can inhibit endothelial cell proliferation, angiogenesis, and tumor growth. Here, KDR is linked to neoplasm.